LAS VEGAS ( FOX5 ) — A pharmaceutical company has begun testing GLP-1 injections designed for obese cats.

According to a New York Times report , Okava Pharmaceuticals is testing a pilot program that involves an implant slightly larger than a microchip that slowly releases the drug over months.

It marks the entry of the popular human weight-loss and diabetes drug class into veterinary medicine.

Early evidence suggests the drugs may help reduce appetite, improve glucose control and promote weight loss in pets, the report states.

The development faces several challenges before reaching the market. Extensive clinical trials still need to be conducted, and costs may be prohibitive for pet owners.

Experts told the New York Times that the drugs would still need to be paired with broader

See Full Page